Broad Nearly Doubles Stock of Illumina Analyzers | GenomeWeb

NEW YORK (GenomeWeb News) – The Broad Institute of MIT and Harvard has bought 22 new Genome Analyzers, nearly doubling its stock of the Illumina-made sequencers, the company said today.

Broad conducts a wide range of biomedical genomics projects, and has worked in a partnership with the San Diego-based life sciences company. Before this purchase, Broad already had 25 of the analyzers in its tool shed, the company said.

In the coming year, Illumina said that it plans to increase the throughput of the analyzer to as much as 95 gigabases of DNA sequence data per run.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.